SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc., an innovative biotechnology company advancing discovery, development and use of transformative therapies across broad therapeutic categories, with a focus on immunology and oncology, including immuno-oncology, announced the appointment of Kathleen LaPorte to the newly created position of Chief Business Officer. Ms. LaPorte has a successful track record of guiding leading life sciences companies with breakthrough technologies, such as Nodality’s proprietary Single Cell Network Profiling (SCNP) technology platform. She will assume responsibility for Nodality’s business development initiatives, as well as the Company’s finance and legal functions, and will report directly to Laura Brege, Nodality’s President and Chief Executive Officer. Ms. LaPorte’s appointment at Nodality is effective immediately.
Ms. Brege commented, “We are excited to welcome Kathy as we continue to expand our senior leadership. Kathy brings strong financial, analytical and strategic background that has been built over years of investing and growing many healthcare and biotech start-ups both as a venture capitalist, and through serving as a key strategic advisor to numerous CEOs. Ms. LaPorte’s entrepreneurial perspective will be instrumental in expanding Nodality’s partnering programs for our breakthrough SCNP technology.”
Ms. LaPorte has served since 2011 as Venture Partner at New Leaf Venture (NLV) Partners, collaborating on sourcing of opportunities with an emphasis on the information convergence sector. She also was a Founding Partner of NLV Partners upon its spin out from the Sprout Group, where she previously had served as General Partner. While at NLV Partners, Ms. LaPorte led investments in and served on the Boards of companies including: ISTA Pharmaceuticals, successfully sold to Bausch + Lomb; Pearl Therapeutics, which was acquired by AstraZeneca, and Prometheus Laboratories, acquired by Nestle SA’s health-science unit. Ms. LaPorte also is a co-founder of angel investing group Health Tech Capital in the digital health space. Previously, she was a Principal at venture capital firm Asset Management Company. Ms. LaPorte received her B.S. degree in biology summa cum laude, Phi Beta Kappa from Yale University and her MBA degree as Arjay Miller Scholar from Stanford University Graduate School of Business.
About Single Cell Network Profiling
Contemporary pharmaceutical research and development remains challenged in producing drugs able to revolutionize the treatment of many of our most intractable diseases. Nodality's proprietary Single Cell Network Profiling (SCNP) offers solutions across broad therapeutic categories that demand higher levels of biological understanding to inform effective drug development decisions. Today, Nodality focuses its SCNP platform on immunology and oncology, including immuno-oncology.
Originally developed at Stanford University, SCNP is a multiparametric flow cytometry-based assay that provides unprecedented insights into diseases by characterizing cell signaling networks in millions of cells at the single cell level. SCNP measures functional protein pathway signaling networks within and between cells, identifying rare cell subsets, such as drug-resistant cells, revealing epigenetic changes in cells, and perceiving cell-cell interactions in complex disease states.
Nodality is advancing drug discovery, therapeutic development, and precision medicine by delivering critical and clinically actionable information to bridge gaps left by traditional R&D approaches. Nodality's proprietary functional biology platform, Single Cell Network Profiling (SCNP), unlocks highly complex intracellular mechanisms and cellular interactions in human diseases and has the power to shed light on some of the pharmaceutical industry's most challenging R&D problems. SCNP enables smarter spending decisions and is applicable across a very broad therapeutic landscape and throughout the full discovery and development process. Nodality has established multi-year strategic collaborations with UCB Pharma S.A. (Euronext Brussels: UCB), Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ), utilizing its SCNP technology to assist the discovery and development of new therapeutic compounds.